Bill Text: NY A02661 | 2023-2024 | General Assembly | Amended

---

Bill Title: Establishes the "Syd O. Sotillo Sickle Cell Treatment Act" which designates sickle cell centers for excellence and outpatient treatment centers.

Spectrum: Strong Partisan Bill (Democrat 10-1)

Status: (Introduced) 2024-05-21 - reported referred to ways and means [A02661 Detail]

Download: New_York-2023-A02661-Amended.html

---

                STATE OF NEW YORK
        ________________________________________________________________________

                                         2661--A

                               2023-2024 Regular Sessions

                   IN ASSEMBLY

                                    January 26, 2023
                                       ___________

        Introduced  by  M.  of  A. HYNDMAN, McDONALD, AUBRY, SAYEGH, CUNNINGHAM,
          EPSTEIN, LUNSFORD, SLATER, WALKER -- read once  and  referred  to  the
          Committee  on  Health  --  recommitted  to  the Committee on Health in
          accordance with Assembly Rule 3, sec. 2 -- committee discharged,  bill
          amended,  ordered reprinted as amended and recommitted to said commit-
          tee

        AN ACT to amend the public health law, in relation to  establishing  the
          "Syd O. Sotillo Sickle Cell Treatment Act"

          The  People of the State of New York, represented in Senate and Assem-
        bly, do enact as follows:

     1    Section 1. Short title. This act shall be known and may  be  cited  as
     2  the "Syd O. Sotillo Sickle Cell Treatment Act".
     3    §  2. The public health law is amended by adding a new section 2807-bb
     4  to read as follows:
     5    § 2807-bb. Sickle cell centers for excellence and outpatient treatment
     6  centers. 1. Centers for sickle cell care  excellence.  The  commissioner
     7  shall  designate  five general hospitals or hospices under article forty
     8  of this chapter, upon successful application, as centers for sickle cell
     9  care excellence. The designations shall be made through  an  application
    10  designed  by  the  department,  and based on service, staffing and other
    11  criteria as developed by the commissioner.  The  centers  of  excellence
    12  shall  provide  specialized sickle cell disease care, treatment, pallia-
    13  tive care, education and related services and shall conduct  specialized
    14  research into the care, treatment and management of sickle cell disease.
    15  Designation  as a center for sickle cell care excellence shall not enti-
    16  tle a center to enhanced reimbursement, but may be utilized in  outreach
    17  and  other  promotional  activities.  Each  center  for sickle cell care
    18  excellence shall affiliate and cooperate with major  centers  of  higher
    19  learning,  including  medical colleges, and life science research insti-
    20  tutes in the state.  The state university shall enter  into  appropriate
    21  legal agreements to enable this cooperation. Each center for sickle cell

         EXPLANATION--Matter in italics (underscored) is new; matter in brackets
                              [ ] is old law to be omitted.
                                                                   LBD05963-03-4
        A. 2661--A                          2

     1  care excellence shall receive two hundred thousand dollars per year from
     2  the  department,  from amounts appropriated for that purpose, to be used
     3  on sickle cell disease research.
     4    2.  Outpatient treatment centers. The commissioner shall designate ten
     5  hospitals, distributed based on sickle cell patient  population  concen-
     6  trations,  as  sickle  cell  outpatient  treatment  centers  which shall
     7  provide patients treatment for sickle cell  disease  as  an  outpatient.
     8  Each  sickle  cell outpatient treatment center shall receive one hundred
     9  thousand dollars per year from the department, from amounts appropriated
    10  for that purpose, to be used to ensure the proper management and  equip-
    11  ping of the centers to care for sickle cell patients.
    12    §  3. Subdivision 8 of section 3331 of the public health law, as added
    13  by section 7-a of part D of chapter 57 of the laws of 2018,  is  amended
    14  to read as follows:
    15    8.  No  opioids  shall  be prescribed to a patient initiating or being
    16  maintained on opioid treatment for pain which has lasted more than three
    17  months or past the time of normal tissue  healing,  unless  the  medical
    18  record contains a written treatment plan that follows generally accepted
    19  national  professional  or  governmental guidelines. The requirements of
    20  this paragraph shall not apply in the case of  patients  who  are  being
    21  treated  for cancer or sickle cell disease that is not in remission, who
    22  are in hospice or other end-of-life care, or whose pain is being treated
    23  as part of palliative care practices.
    24    § 4. This act shall take effect immediately.